Imaging in Stem Cell Transplant and Cell-based Therapy

83

8. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab ther­
   apy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.


9. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High­dose melphalan with autologous
   bone marrow transplantation for multiple myeloma. Blood. 1986;67(5):1298–301.


10. Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, et al. Hematopoietic stem cell
    transplantation for multiple myeloma: guidelines from the American Society for Blood and
    Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(7):1155–66.


11. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide
    and hematopoietic­cell transplantation for multiple myeloma. N Engl J  Med. 2006;354(10):
    1021–30.


12. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, et al. Long­term outcome
    results of the first tandem autotransplant trial for multiple myeloma. Br J  Haematol.
    2006;135(2):158–64.


13. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, et al. Pomalidomide
    (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide
    refractory multiple myeloma (MM). Leukemia. 2010;24(11):1934–9.


14. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab mono­
    therapy in patients with treatment­refractory multiple myeloma (SIRIUS): an open­label, ran­
    domised, phase 2 trial. Lancet. 2016;S0140­6736(15):01120–4.


15. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study
    of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609–17.


16. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, et al. A ran­
    domized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and
    refractory multiple myeloma. Blood. 2006;108(10):3458–64.


17. Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, et al. The investiga­
    tional proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncol.
    2015;11(8):1153–68.


18. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, et  al.
    PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients
    with relapsed and bortezomib­refractory myeloma. Blood. 2013;122(14):2331–7.


19. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single­
    agent carfilzomib (PX­171­003­A1) in patients with relapsed and refractory multiple myeloma.
    Blood. 2012;120(14):2817–25.


20. Stewart AK, Richardson PG, San­Miguel JF.  How I treat multiple myeloma in younger
    patients. Blood. 2009;114(27):5436–43.


21. Mohty M, Richardson PG, McCarthy PL, Attal M. Consolidation and maintenance therapy for
    multiple myeloma after autologous transplantation: where do we stand? Bone Marrow
    Transplant. 2015;50(8):1024–9.


22. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last:
    defining criteria and providing the evidence. Blood. 2014;124(20):3043–51.


23. Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N. Clinical experiences
    with sarcolysin in neoplastic diseases. Ann N Y Acad Sci. 1958;68(3):1128–32.


24. Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD.  Melphalan therapy for
    plasma cell myeloma. Blood. 1968;31(1):1–10.


25. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, et  al. Treatment for
    multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
    JAMA. 1969;208(9):1680–5.


26. McElwain TJ, Powles RL.  High­dose intravenous melphalan for plasma­cell leukaemia and
    myeloma. Lancet. 1983;2(8354):822–4.


27. Selby P. High­dose chemotherapy. Chemioterapia. 1987;6(2 Suppl):675–7.


28. Cunningham D, Paz­Ares L, Gore ME, Malpas J, Hickish T, Nicolson M, et  al. High­dose
    melphalan for multiple myeloma: long­term follow­up data. J Clin Oncol. 1994;12(4):764–8.


29. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, et  al. High­dose
    chemoradiotherapy and autologous bone marrow transplantation for resistant multiple
    myeloma. Blood. 1987;70(3):869–72.

5 Stem Cell Transplantation for Multiple Myeloma